CDHR4
gene geneOn this page
Also known as VLLR9392
Summary
CDHR4 (cadherin related family member 4, HGNC:34527) is a protein-coding gene on chromosome 3p21.31, encoding Cadherin-related family member 4 (A6H8M9). Cadherins are calcium-dependent cell adhesion proteins.
Predicted to enable calcium ion binding activity. Predicted to be involved in cell adhesion. Predicted to be located in membrane. Predicted to be active in plasma membrane.
Source: NCBI Gene 389118 — RefSeq curated summary.
At a glance
- GWAS associations: 11
- Clinical variants (ClinVar): 142 total
- MANE Select transcript:
NM_001007540
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:34527 |
| Approved symbol | CDHR4 |
| Name | cadherin related family member 4 |
| Location | 3p21.31 |
| Locus type | gene with protein product |
| Status | Approved |
| Aliases | VLLR9392 |
| Ensembl gene | ENSG00000187492 |
| Ensembl biotype | protein_coding |
| Entrez | 389118 |
Gene structure
Transcript identifiers
Ensembl transcripts: 6 — 4 protein_coding, 1 nonsense_mediated_decay, 1 protein_coding_CDS_not_defined
ENST00000343366, ENST00000412678, ENST00000460430, ENST00000462108, ENST00000487256, ENST00000487666
RefSeq mRNA: 1 — MANE Select: NM_001007540
NM_001007540
CCDS: CCDS46829
Canonical transcript exons
ENST00000412678 — 19 exons
| Exon | Start | End |
|---|---|---|
| ENSE00001367155 | 49799764 | 49799873 |
| ENSE00001368163 | 49799247 | 49799437 |
| ENSE00001616795 | 49791441 | 49791468 |
| ENSE00001629523 | 49793583 | 49793722 |
| ENSE00001645938 | 49792854 | 49793074 |
| ENSE00001646668 | 49795628 | 49795764 |
| ENSE00001670653 | 49794608 | 49794701 |
| ENSE00001678315 | 49796922 | 49797032 |
| ENSE00001690608 | 49795196 | 49795379 |
| ENSE00001741833 | 49798826 | 49798917 |
| ENSE00001746368 | 49793803 | 49794006 |
| ENSE00001753570 | 49798994 | 49799156 |
| ENSE00001759451 | 49793161 | 49793311 |
| ENSE00001772903 | 49794947 | 49795100 |
| ENSE00001796634 | 49795943 | 49796046 |
| ENSE00001796912 | 49792468 | 49792610 |
| ENSE00003564278 | 49791714 | 49791801 |
| ENSE00003593266 | 49790732 | 49790887 |
| ENSE00003654186 | 49791903 | 49791959 |
Expression profiles
Bgee: expression breadth ubiquitous, 108 present calls, max score 99.40.
FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.2525 / max 50.2317, expressed in 67 samples.
FANTOM5 promoters (2 alternative TSS)
| Promoter ID | TPM avg | Samples expressed |
|---|---|---|
| 42277 | 0.1387 | 43 |
| 42278 | 0.1138 | 40 |
Top tissues by expression
122 total, by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| right uterine tube | UBERON:0001302 | 99.40 | gold quality |
| olfactory segment of nasal mucosa | UBERON:0005386 | 91.97 | gold quality |
| fallopian tube | UBERON:0003889 | 88.96 | gold quality |
| left uterine tube | UBERON:0001303 | 79.98 | gold quality |
| right lung | UBERON:0002167 | 79.14 | gold quality |
| right testis | UBERON:0004534 | 78.85 | gold quality |
| male germ line stem cell (sensu Vertebrata) in testis | CL:0000089 ∩ UBERON:0000473 | 78.51 | gold quality |
| left testis | UBERON:0004533 | 77.64 | gold quality |
| testis | UBERON:0000473 | 76.88 | gold quality |
| endocervix | UBERON:0000458 | 71.70 | gold quality |
| lung | UBERON:0002048 | 64.95 | gold quality |
| upper lobe of left lung | UBERON:0008952 | 64.62 | gold quality |
| endometrium | UBERON:0001295 | 61.80 | gold quality |
| right coronary artery | UBERON:0001625 | 61.25 | gold quality |
| uterine cervix | UBERON:0000002 | 60.85 | gold quality |
| popliteal artery | UBERON:0002250 | 59.70 | gold quality |
| tibial artery | UBERON:0007610 | 59.66 | gold quality |
| left coronary artery | UBERON:0001626 | 59.30 | gold quality |
| thoracic aorta | UBERON:0001515 | 58.93 | gold quality |
| ascending aorta | UBERON:0001496 | 58.78 | gold quality |
| descending thoracic aorta | UBERON:0002345 | 58.69 | gold quality |
| myometrium | UBERON:0001296 | 57.16 | gold quality |
| stromal cell of endometrium | CL:0002255 | 56.84 | gold quality |
| body of uterus | UBERON:0009853 | 56.60 | gold quality |
| muscle layer of sigmoid colon | UBERON:0035805 | 56.28 | gold quality |
| zone of skin | UBERON:0000014 | 56.03 | gold quality |
| skin of leg | UBERON:0001511 | 55.93 | gold quality |
| skin of abdomen | UBERON:0001416 | 55.86 | gold quality |
| tibial nerve | UBERON:0001323 | 55.85 | gold quality |
| subcutaneous adipose tissue | UBERON:0002190 | 54.46 | gold quality |
Single-cell (SCXA)
Detected in 1 experiment(s), a significant marker in 1.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-ANND-3 | yes | 11.17 |
Regulation
Is transcription factor: no
miRNA regulators (miRDB)
7 targeting CDHR4, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):
| miRNA | Max score | Avg score | miRNA target_count |
|---|---|---|---|
| HSA-MIR-3692-3P | 99.98 | 70.27 | 2139 |
| HSA-MIR-4641 | 99.28 | 66.64 | 744 |
| HSA-MIR-2054 | 99.20 | 68.89 | 1699 |
| HSA-MIR-3650 | 97.88 | 64.89 | 693 |
| HSA-MIR-4690-3P | 97.02 | 64.72 | 981 |
| HSA-MIR-5685 | 97.02 | 64.34 | 1004 |
| HSA-MIR-6856-3P | 96.47 | 66.27 | 781 |
Cross-species orthologs
2 orthologs
| Organism | Symbol | Gene ID |
|---|---|---|
| mus_musculus | Cdhr4 | ENSMUSG00000032595 |
| rattus_norvegicus | Cdhr4 | ENSRNOG00000061650 |
Paralogs (61): PCDHB4 (ENSG00000081818), PCDHA6 (ENSG00000081842), PCDHGA2 (ENSG00000081853), PCDHB2 (ENSG00000112852), PCDHB3 (ENSG00000113205), PCDHB5 (ENSG00000113209), PCDHB6 (ENSG00000113211), PCDHB7 (ENSG00000113212), PCDHB15 (ENSG00000113248), PCDH12 (ENSG00000113555), PCDH17 (ENSG00000118946), PCDHB8 (ENSG00000120322), PCDHB10 (ENSG00000120324), PCDHB14 (ENSG00000120327), PCDHB12 (ENSG00000120328), PCDH8 (ENSG00000136099), PCDH10 (ENSG00000138650), PCDH15 (ENSG00000150275), PCDH19 (ENSG00000165194), CDH16 (ENSG00000166589), PCDHB1 (ENSG00000171815), PCDHB9 (ENSG00000177839), PCDHB13 (ENSG00000187372), PCDH18 (ENSG00000189184), PCDHB11 (ENSG00000197479), PCDHGA1 (ENSG00000204956), PCDHA9 (ENSG00000204961), PCDHA8 (ENSG00000204962), PCDHA7 (ENSG00000204963), PCDHA5 (ENSG00000204965), PCDHA4 (ENSG00000204967), PCDHA2 (ENSG00000204969), PCDHA1 (ENSG00000204970), PCDHA13 (ENSG00000239389), PCDHGC3 (ENSG00000240184), PCDHGC5 (ENSG00000240764), PCDHGC4 (ENSG00000242419), PCDHAC2 (ENSG00000243232), PCDHAC1 (ENSG00000248383), PCDHA11 (ENSG00000249158)
Protein
Protein identifiers
Cadherin-related family member 4 — A6H8M9 (reviewed: A6H8M9)
Alternative names: Cadherin-like protein 29
All UniProt accessions (4): A6H8M9, E9PFE8, H7C4N6, H7C5B2
UniProt curated annotations — full annotation on UniProt →
Function. Cadherins are calcium-dependent cell adhesion proteins. They preferentially interact with themselves in a homophilic manner in connecting cells; cadherins may thus contribute to the sorting of heterogeneous cell types.
Subcellular location. Membrane.
Isoforms (2)
| UniProt ID | Names | Canonical? |
|---|---|---|
| A6H8M9-1 | 1 | yes |
| A6H8M9-2 | 2 |
RefSeq proteins (1): NP_001007541* (*=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR002126 | Cadherin-like_dom | Domain |
| IPR015919 | Cadherin-like_sf | Homologous_superfamily |
| IPR020894 | Cadherin_CS | Conserved_site |
| IPR050971 | Cadherin-domain_protein | Family |
Pfam: PF00028
UniProt features (13 total): domain 4, splice variant 2, topological domain 2, signal peptide 1, chain 1, sequence variant 1, transmembrane region 1, glycosylation site 1
Structure
Experimental structures (PDB)
0 structures.
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-A6H8M9-F1 | 78.90 | 0.34 |
Functional residue map
Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.
Glycosylation sites (1): 242
Function
Pathways and Gene Ontology
Reactome pathways
0 pathways
MSigDB gene sets: 37 (showing top):
GRAESSMANN_APOPTOSIS_BY_SERUM_DEPRIVATION_UP, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_UP, GOBP_CELL_CELL_ADHESION, WANG_TUMOR_INVASIVENESS_UP, GOMF_CELL_ADHESION_MOLECULE_BINDING, MIKKELSEN_ES_ICP_WITH_H3K4ME3_AND_H3K27ME3, MIKKELSEN_NPC_ICP_WITH_H3K4ME3, chr3p21, ZBTB12_TARGET_GENES, MIR6856_3P, MIR4641, GSE15324_NAIVE_VS_ACTIVATED_ELF4_KO_CD8_TCELL_DN, GAO_ESOPHAGUS_25W_C1_CILIATED_EPITHELIAL_CELLS, DESCARTES_MAIN_FETAL_CILIATED_EPITHELIAL_CELLS, DESCARTES_FETAL_CEREBRUM_ASTROCYTES
GO Biological Process (2): cell adhesion (GO:0007155), homophilic cell-cell adhesion (GO:0007156)
GO Molecular Function (2): calcium ion binding (GO:0005509), cell adhesion molecule binding (GO:0050839)
GO Cellular Component (2): plasma membrane (GO:0005886), membrane (GO:0016020)
GO top-level categories
Rollup of top GO terms by namespace:
| Category | Terms |
|---|---|
| cellular process | 1 |
| cell-cell adhesion | 1 |
| metal ion binding | 1 |
| protein binding | 1 |
| membrane | 1 |
| cell periphery | 1 |
| cellular anatomical structure | 1 |
Protein interactions and networks
STRING
316 interactions, top by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| CDHR4 | IP6K1 | Q92551 | 528 |
| CDHR4 | RNF123 | Q5XPI4 | 522 |
| CDHR4 | MON1A | Q86VX9 | 496 |
| CDHR4 | CDH23 | Q9H251 | 483 |
| CDHR4 | TRAIP | Q9BWF2 | 460 |
| CDHR4 | ZACN | Q401N2 | 452 |
| CDHR4 | KNCN | A6PVL3 | 432 |
| CDHR4 | CDHR2 | Q9BYE9 | 432 |
| CDHR4 | CAMKV | Q8NCB2 | 419 |
| CDHR4 | C3orf62 | Q6ZUJ4 | 399 |
| CDHR4 | EFCAB8 | A8MWE9 | 397 |
| CDHR4 | MST1R | Q04912 | 378 |
| CDHR4 | R3HDM1 | Q15032 | 364 |
| CDHR4 | KLHL3 | Q9UH77 | 363 |
| CDHR4 | UCMA | Q8WVF2 | 354 |
IntAct
4 interactions, top by confidence:
| A | B | Type | Score |
|---|---|---|---|
| CDHR4 | HSPA5 | psi-mi:“MI:0914”(association) | 0.350 |
| CDHR4 | TAPBP | psi-mi:“MI:0914”(association) | 0.350 |
| KLHL22 | TRAV18 | psi-mi:“MI:0914”(association) | 0.350 |
BioGRID (68): HSPA5 (Affinity Capture-MS), MRC2 (Affinity Capture-MS), COMMD9 (Affinity Capture-MS), PTPRK (Affinity Capture-MS), FBXO2 (Affinity Capture-MS), DNAJC16 (Affinity Capture-MS), COMMD3 (Affinity Capture-MS), METRNL (Affinity Capture-MS), NAGLU (Affinity Capture-MS), PON2 (Affinity Capture-MS), CNTNAP3B (Affinity Capture-MS), POLD3 (Affinity Capture-MS), ART5 (Affinity Capture-MS), SKP1 (Affinity Capture-MS), TTC37 (Affinity Capture-MS)
ESM2 similar proteins: A0A140LHF2, A6H8M9, A7LCJ3, A8E0Y8, D3YX43, D3YZF7, O14498, O15197, O70394, O70540, P01877, P0C0K6, P0C788, P0DP72, P35590, P40223, P43121, P50895, P70289, Q00657, Q06418, Q06805, Q15109, Q28173, Q5BK54, Q5NVQ6, Q5TJE4, Q61790, Q61826, Q62151, Q62230, Q63495, Q64612, Q6UVK1, Q6UWB1, Q7Z442, Q86VR7, Q8IZF5, Q8R2Y2, Q8VHY0
Diamond homologs: A6H8M9, O55134, O88338, P34616, Q5DRA2, Q5DRC0, Q5DRC3, Q5DRC4, Q5DRF3, Q91Y13, Q9NPG4, Q9Y5F6, Q9Y5H2, Q9Y5I1, B2KI42, O02840, O54800, O55075, O60330, O88278, O93319, P09803, P15116, P19534, P33146, P33148, P33151, P33152, P55280, P55284, P55285, P55286, P55287, P55288, P70407, P97291, P97326, Q03763, Q13634, Q3SWX5
SIGNOR signaling
0 interactions.
Disease & clinical
Clinical variants and AI predictions
ClinVar
142 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 0 |
| Likely pathogenic | 0 |
| Uncertain significance | 117 |
| Likely benign | 18 |
| Benign | 0 |
Top pathogenic / likely-pathogenic (0)
SpliceAI
2783 predictions. Top by Δscore:
| Variant | Effect | Δscore |
|---|---|---|
| 3:49792535:C:CT | donor_gain | 1.0000 |
| 3:49792852:A:AC | donor_gain | 1.0000 |
| 3:49792853:C:CC | donor_gain | 1.0000 |
| 3:49793155:CCCTA:C | donor_loss | 1.0000 |
| 3:49793156:CCTAC:C | donor_loss | 1.0000 |
| 3:49793157:CTAC:C | donor_loss | 1.0000 |
| 3:49793158:TACCT:T | donor_loss | 1.0000 |
| 3:49793308:CATC:C | acceptor_gain | 1.0000 |
| 3:49793310:TC:T | acceptor_gain | 1.0000 |
| 3:49793311:CC:C | acceptor_gain | 1.0000 |
| 3:49793312:C:CC | acceptor_gain | 1.0000 |
| 3:49793312:CTGCA:C | acceptor_loss | 1.0000 |
| 3:49793313:T:C | acceptor_loss | 1.0000 |
| 3:49793802:CCG:C | donor_gain | 1.0000 |
| 3:49793855:A:AC | donor_gain | 1.0000 |
| 3:49794606:A:AC | donor_gain | 1.0000 |
| 3:49794607:C:CC | donor_gain | 1.0000 |
| 3:49795194:A:AC | donor_gain | 1.0000 |
| 3:49795195:C:CC | donor_gain | 1.0000 |
| 3:49795195:CA:C | donor_gain | 1.0000 |
| 3:49795376:TCTG:T | acceptor_loss | 1.0000 |
| 3:49795377:CTG:C | acceptor_gain | 1.0000 |
| 3:49795377:CTGC:C | acceptor_loss | 1.0000 |
| 3:49795378:TG:T | acceptor_gain | 1.0000 |
| 3:49795379:GCTGC:G | acceptor_loss | 1.0000 |
| 3:49795380:C:CC | acceptor_gain | 1.0000 |
| 3:49795381:T:G | acceptor_loss | 1.0000 |
| 3:49795383:CA:C | acceptor_gain | 1.0000 |
| 3:49795384:A:AC | acceptor_gain | 1.0000 |
| 3:49795384:A:C | acceptor_gain | 1.0000 |
AlphaMissense
5118 scored. Top likely-pathogenic:
| Variant | Protein change | am_pathogenicity |
|---|---|---|
| 3:49793055:G:C | F598L | 0.955 |
| 3:49793055:G:T | F598L | 0.955 |
| 3:49793057:A:G | F598L | 0.955 |
| 3:49795215:A:G | C338R | 0.940 |
| 3:49793963:G:C | F441L | 0.939 |
| 3:49793963:G:T | F441L | 0.939 |
| 3:49793965:A:G | F441L | 0.939 |
| 3:49795214:C:G | C338S | 0.938 |
| 3:49795215:A:T | C338S | 0.938 |
| 3:49793056:A:G | F598S | 0.937 |
| 3:49793593:A:T | I538N | 0.936 |
| 3:49793822:A:C | F488L | 0.935 |
| 3:49793822:A:T | F488L | 0.935 |
| 3:49793824:A:G | F488L | 0.935 |
| 3:49795367:A:T | V287D | 0.932 |
| 3:49795047:C:T | C362Y | 0.924 |
| 3:49795048:A:G | C362R | 0.923 |
| 3:49795945:G:C | F236L | 0.921 |
| 3:49795945:G:T | F236L | 0.921 |
| 3:49795947:A:G | F236L | 0.921 |
| 3:49796041:G:C | F204L | 0.919 |
| 3:49796041:G:T | F204L | 0.919 |
| 3:49796043:A:G | F204L | 0.919 |
| 3:49790865:A:C | F778L | 0.918 |
| 3:49790865:A:T | F778L | 0.918 |
| 3:49790867:A:G | F778L | 0.918 |
| 3:49791463:A:C | F763L | 0.916 |
| 3:49791463:A:T | F763L | 0.916 |
| 3:49791465:A:G | F763L | 0.916 |
| 3:49796985:G:C | F181L | 0.913 |
dbSNP variants (sampled 300 via entrez): RS1000345506 (3:49792062 T>A,C), RS1001005784 (3:49802427 G>T), RS1001071331 (3:49804000 C>A), RS1001100350 (3:49797073 G>C), RS1001266151 (3:49797857 G>A), RS1001298565 (3:49797594 G>C), RS1001425750 (3:49791114 G>T), RS1001550887 (3:49798176 A>G), RS1001686683 (3:49798664 C>A), RS1001695651 (3:49791034 T>C), RS1001876928 (3:49790823 T>C), RS1002119886 (3:49803386 C>T), RS1002407139 (3:49803574 G>A,C), RS1002691548 (3:49796992 C>T), RS1003580213 (3:49802532 C>A,T)
Disease associations
OMIM: gene `` | disease phenotypes:
GenCC curated gene-disease
Mondo (1): breast ductal adenocarcinoma (MONDO:0005590)
Orphanet (0):
HPO phenotypes
0 total (0 of 0 shown, HPO-id order):
GWAS associations
11 associations (top):
| Study | Trait | p-value |
|---|---|---|
| GCST005951_49 | Body mass index | 1.000000e-08 |
| GCST006269_602 | General cognitive ability | 2.000000e-13 |
| GCST006920_7 | Regular attendance at a gym or sports club | 6.000000e-10 |
| GCST006922_9 | Regular attendance at a religious group | 3.000000e-08 |
| GCST007044_11 | Extremely high intelligence | 4.000000e-08 |
| GCST010002_422 | Refractive error | 4.000000e-14 |
| GCST010698_80 | Subcortical volume (min-P) | 3.000000e-24 |
| GCST010699_110 | Brain morphology (min-P) | 4.000000e-08 |
| GCST010701_52 | Cortical surface area (MOSTest) | 1.000000e-16 |
| GCST010702_36 | Subcortical volume (MOSTest) | 1.000000e-10 |
| GCST010703_262 | Brain morphology (MOSTest) | 2.000000e-13 |
EFO canonical traits (4, from GWAS)
| EFO ID | Trait name |
|---|---|
| EFO:0004340 | body mass index |
| EFO:0004337 | intelligence |
| EFO:0009592 | social interaction measurement |
| EFO:0004346 | neuroimaging measurement |
MeSH disease descriptors (1)
| Descriptor | Name | Tree numbers |
|---|---|---|
| D018270 | Carcinoma, Ductal, Breast | C04.557.470.200.025.232.500; C04.557.470.615.132.500; C04.588.180.390; C17.800.090.500.390 |
Drugs & pharmacology
Drug and pharmacology data
Is drug target: no
PharmGKB: 1 entry (VIP=true, CPIC=false)
CTD chemical–gene interactions
9 total (human), top 9 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| aristolochic acid I | increases expression | 1 |
| sodium arsenite | decreases expression | 1 |
| butyraldehyde | decreases expression | 1 |
| Air Pollutants | increases abundance, increases expression | 1 |
| Estradiol | increases expression | 1 |
| Smoke | increases abundance, increases expression | 1 |
| Tobacco Smoke Pollution | decreases expression | 1 |
| Aflatoxin B1 | increases methylation | 1 |
| Okadaic Acid | increases expression | 1 |
Clinical trials (associated diseases)
11 trials via MONDO — disease-level, not drug-specific.
| Trial | Phase | Status | Title |
|---|---|---|---|
| NCT03414970 | PHASE3 | ACTIVE_NOT_RECRUITING | Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer |
| NCT00461344 | PHASE2 | TERMINATED | Docetaxel + Doxorubicin as Neoadjuvant Chemotherapy in Patients With Breast Cancer |
| NCT07499999 | PHASE2 | NOT_YET_RECRUITING | Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk for Breast Cancer |
| NCT00637364 | PHASE1/PHASE2 | SUSPENDED | High Intensity Focused Ultrasound Tumor Treatment for Pancreatic Cancer Pain |
| NCT02779855 | PHASE1/PHASE2 | COMPLETED | Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer |
| NCT01753908 | EARLY_PHASE1 | COMPLETED | Broccoli Sprout Extract in Treating Patients With Breast Cancer |
| NCT01796041 | EARLY_PHASE1 | COMPLETED | Intraoperative Imaging of Breast Cancer With Indocyanine Green |
| NCT01208974 | Not specified | ACTIVE_NOT_RECRUITING | Nipple-Areola Complex (NAC) Irradiation After Nipple-Sparing Mastectomy and Reconstruction |
| NCT01875198 | Not specified | TERMINATED | Oncologic Impact of Splenectomy-omitting Radical Pancreatectomy in Well-selected Left-sided Pancreatic Cancer |
| NCT03543397 | Not specified | UNKNOWN | MRI in Ductal Carcinoma in Situ (DCIS) |
| NCT03834532 | Not specified | COMPLETED | Living Well After Breast Surgery |
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.